Centre for Complementary Medicine, Department of Internal Medicine II, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
Translational Complementary Medicine, Department of Pharmaceutical Sciences, University of Basel, Basel, Switzerland.
Complement Med Res. 2023;30(5):386-392. doi: 10.1159/000530184. Epub 2023 Mar 16.
Viscum album L. (VA) preparations possess immunomodulatory properties and are used in complementary medicine to support cancer therapy. It is unclear if there is an impact of VA on the expression of immune checkpoint proteins on the surface of cancer cells. This study was designed to investigate the role of commercially available VA preparations on checkpoint programmed death ligand 1, 2 (PD-L1, PD-L2) and on major histocompatibility complex class I (MHC-I).
Four human cancer cell lines (prostate, colon, lung, and breast) were assayed for their PD-L1, PD-L2, and MHC-I level after stimulation with interferon-gamma (IFN-γ). The toxicity of mistletoe preparations for the cells was analysed. Afterwards, the effect of mistletoe preparations on the PD ligands and MHC-I was investigated.
Surface protein analysis demonstrated that all tested tumour cell lines increased the PD-L1, PD-L2, and MHC-I-expression, but to different extents, after IFN-γ stimulation. Treatment with VA extracts did not influence the viability of the cells. The expression of PD ligands and MHC-I was not affected by incubation with the VA preparations.
Our investigation concludes that VA treatment does not interfere with the expression of PD ligands or MHC-I among selected cancer cells.
槲寄生 L.(VA)制剂具有免疫调节特性,在补充医学中用于支持癌症治疗。目前尚不清楚 VA 是否会影响癌细胞表面免疫检查点蛋白的表达。本研究旨在研究市售 VA 制剂对检查点程序性死亡配体 1、2(PD-L1、PD-L2)和主要组织相容性复合体 I(MHC-I)的作用。
用干扰素-γ(IFN-γ)刺激四种人癌细胞系(前列腺、结肠、肺和乳腺)后,检测其 PD-L1、PD-L2 和 MHC-I 水平。分析槲寄生制剂对细胞的毒性。然后,研究槲寄生制剂对 PD 配体和 MHC-I 的影响。
表面蛋白分析表明,所有测试的肿瘤细胞系在 IFN-γ刺激后,PD-L1、PD-L2 和 MHC-I 的表达均增加,但程度不同。VA 提取物处理不影响细胞活力。PD 配体和 MHC-I 的表达不受与 VA 制剂孵育的影响。
我们的研究得出结论,VA 治疗不会干扰选定癌细胞中 PD 配体或 MHC-I 的表达。